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5,8,1 I-Icosatrienoic acid (20: 3n-9), a fatty acid associated with platelet hyperactivity, was oxygenated by 
platelet lipoxygenase. The end-product of this pathway was purified by high-performance liquid chromatog- 
raphy (HPLC) and characterized as 12-hydroxy-5,8,10-icosatrienoic acid [12-OH-20: 3(5,8,10)] by capillary 
gas-liquid mass spectrometry. When tested upon platelet aggregation, 12-OH-20: 3(5,8,10) exhibited a bi- 
phasic effect. At low concentrations (below 5 x lo-’ M) it potentiated aggregation but inhibited it at higher 
levels, a pattern similar to that obtained with prostaglandin E,. However, since the amounts of 12-OH- 
20: 3(5,8.10) generated under thrombin stimulation are in the range of concentrations with potentiating ef- 
fects, it seems that the 12-OH derivative is responsible for the hyperaggrebility of 20: 3n-9-rich platelets. 
Human platelet Lipoxygenase-5,8,11-icosatrienoic acid Platelet aggregation 
1. INTRODUCTION 
High saturated fat diets, with or without linoleic 
acid deficiency, promote the accumulation of 
20 : 3n-9 in blood lipids and platelets [ 1-3). An in- 
crease of 20: 3n-9 in platelet phospholipids 
resulting from saturated fat feeding has been 
associated with the enhancement of certain platelet 
functions, especially platelet aggregation induced 
by thrombin both in animals [2,3] and man [4]. We 
have reported that enriching human platelets with 
20 : 30n-9 in vitro markedly enhances the response 
of platelets to aggregation through the lipox- 
ygenase pathway [5]. On the other hand, we have 
also found that several ipoxygenase products, par- 
Abbreviations: PG, prostaglandin; 20: 3n-9, 5,8,1 l-ico- 
satrienoic acid; U46619, 9-methano analogue of PGH2; 
HPLC, high-performance liquid chromatography; TLC, 
thin-layer chromatography; GC-MS, gas-liquid chroma- 
tography-mass spectrometry; TMS, trimethylsilyl; 
BSTFA, bis-silyl trifluoroacetamide 
titularly from arachidonic acid, inhibit 
stereospecifically PGHz-induced platelet aggrega- 
tion [6]. Here, the platelet lipoxygenase end- 
product of 20:3n-9 was purified, identified by 
mass spectrometry and its biologic effect tested on 
platelet aggregation. 
2. MATERIALS AND METHODS 
Human platelets, isolated from their plasma as 
described [7], were homogenized by sonication. 
The homogenate was centrifuged for 20 min at 
13000 x g to pellet most of the granules and 
mitochondria. The supernatant used as a platelet 
lipoxygenase source was incubated for 20 min with 
10e4 M [14C]20: 3n-9 (1.6 Ci/mol) chemically syn- 
thesized [8]. After acidic (pH 3) extraction with 
diethyl ether, the lipids were separated by TLC us- 
ing a mixture of hexane-diethyl ether-acetic acid 
(60 : 40: 1, v/v) as eluent. The radiolabelled 
substance migrating like 12- or 15-monohydroxy- 
icosaenoic acids was scraped from the plate, ex- 
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tracted with diethyl ether and further purified by 
reversed phase HPLC [6]. 
Mass spectra of the 20:3n-9 monohydroxy 
derivative and its hydrogenated form were per- 
formed with an LKB 2085 capillary gas-liquid 
chromatography-mass spectrometer (K-MS). 
These substances were analysed as methyl esters 
(after treatment with an ethereal solution saturated 
with diazomethane for 20 min, at room 
temperature) and trimethylsilyl ethers (after treat- 
ment with BSTFA-hexane, 50: 50, v/v, for 1 h at 
60°C). The hydrogenated form of the OH-20: 3 
was obtained by hydrogen bubbling in a 
methanolic solution of the derivative in the 
presence of platinum. Fragmentation of the 
molecules was performed by electron impact 
(20 eV) and the ions detected with an accelerating 
voltage of 3.5 kV and a trap current of 50 fitA 191. 
Platelet aggregation was performed on normal 
human platelets isolated from their plasma [7]. 
The aggregating agents, thrombin or the 
9-methano analogue of PGH;? (U46619) which is a 
thromboxane A2 mimetic, and 12-OH- 
20:3(5,8,10) diIuted in ethanol (0.50/o) were 
simultaneously added to platelets. Platelet aggre- 
gation was then measured according to Born’s 
technique [lo]. The percentage of aggregation was 
determined after a 5 min incubation period in 
comparison to the control (ethanol alone). 
3. RESULTS AND DISCUSSION 
The monohydroxy derivative obtained by in- 
cubating 20: 3n-9 with a platelet subfraction con- 
taining the lipoxygenase (microsomes + cytosol) 
was pre-purified by TLC where it co-chroma- 
tographed with 12- or 15-hydroxyicosatetraenoic 
acid (12- or 15HETE). The hydroxy derivative of 
20: 3n-9 was further purified by reverse-phase (rp)- 
HPLC. Fig. 1 gives an example of this purification. 
The retention time of the monohydroxy derivative 
of 20: 3n-9 was slightly longer than that of 20: 3n-6 
(12-OH-8,10,14-20: 3) indicating that it is slightly 
less polar. The hydroxy derivative of 20: 3n-9 was 
then purified on a semi-preparative scale for 
further studies. The UV spectrum of the com- 
pound then purified (not shown) presented a max- 
imal absorbance at 235 nm. Spectra with a similar 
shape have been described for other monohydroxy 
derivatives of long-chain polyunsaturated fatty 
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Fig. 1. HPLC profile of the 20:3(n-9) monohydroxy 
derivative vs that of IZHETE and 12-OH-20: 3(8,10,14) 
on a 25 cm, l/4 inch column packed with nucleosil CIS, 
5 pm. The mobile phase [methanol-water (acidified to 
pH 3 with acetic acid), X:24, v/v] was used at 
1.0 ml/min. UV detection performed at 234 nm. 
acids. They are characterized by the presence of a 
cis-frans conjugated double bond with a hydroxyl 
or hydroperoxyl group in position a of the tram 
double bond [11,12], The carbon position of the 
hydroxy derivative of 20: 3n-9 was investigated by 
capillary GC-MS [9]. The mass spectrum of the 
methyl ester, trimethylsilyl ether derivative (fig.2, 
left) shows a main peak at m/z 267 (fragment from 
CS to CZO, containing the OTMS) and a second 
peak at m/z 295 (fragment from Ci to Ci2, in- 
cluding the OTMS). After hydrogenation of the 
latter derivative as in other studies 191, the mass 
spectrum (fig.2, right) shows two main fragments 
at m/z 215 and 301 corresponding to C12--GO and 
Ci-C~Z, respectively (both containing the OTMS 
group). These spectra confirm that the hydroxyl 
group of the monohydroxy derivative produced 
from 20: 3n-9 by human platelets is in fact at the 
12 position. 
Purified by semi-preparative rp-HPLC, 12-OH- 
20: 3(5,8,10) was quantified by both its specific 
radioactivity (according to that of the precursor) 
and its absorbance at 235 nm, using the same 
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molar coefficient of abs5rption (30~~ as for 
other ~~~~~~~~~~~ derivatives from i4xmenttic 
acids 112-141, According to its concentrations 
12OH-20: 3(5,8,10) exerted a biphasic effect on 
platelet aggregation induced either by thrombin or 
U46&19 (fig.3). We have reported that under 
similar experimental conditions, PC&-induced 
aggregation is affected by lipaxygenase derivatives 
of other fatty acids in a stereospecific manner 161. 
Mowewer, whereas the other active derivatives in- 
hibit~~ the aggregation at any concentrations 
12-OW-20 : 3(5,8, IO) potentiates ~~~re~ation at 
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concentrations below 0.5 x NV5 M as shown here. 
In fact, the pattern sf 12-CM-20: 3(5,8, IO) activity 
on aggregation appears to be very simifar to that 
observed with FGEt tested under similar condi- 
tions (fig.3). PGEz is known to exert a biphasic ef- 
fect on ADP-induced aggregation [15,16f. 
We have shown that 20: 3n-9 is able to poten- 
tiate platelet aggregation through a mechanism in- 
volving the lipoxygenase pathway [5]. In the same 
study we found that 20:3n-9-rich platelets may 
generate 2.1 nmol (per IO9 platelets) of lipox- 
ygenase nd-product when triggered with 0.1 U/ml 
Fig.2. Mass spectra of 20: 3(n-9) mono~~d~o~y derivative (left) and its hydrogenated form (right). These suhst~c~s 
were analysed as methyI esters, trimethylsII~1 ethers. The fragments, especially from the hydrogenated erivative (m/z = 
215 and 3011, clearly indicate that 20:3@-9) ox~~e~atio~ was done on C~Z. 
Fig.3. InfI uenee of 12-OH-ZU: 3(5,8,10) at different 
concentrations on aggregation induced by thrombin 
(0.015 U/ml) or the 9-methano anaIogue of PGH2. In 
comparison, the effect of PGEz on aggregation induced 
by the 9-methano analogue of PGHa is also shewn. 
Results are expressed as the mean k SE of the change 
@‘a) in reactivity in the presence (D) or absence (G) of the 
moIeeuIe as a percentage of the control {Cl+ IO0 x 
@ - C)I’C. Each point represent5 the pooled results of 
4-15 experiments. 
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thrombin for 4 min. We extrapolate that this 
amount corresponds to approx. 0.7 nmol/ml 
platelets at physiological concentrations. Under 
these conditions, the concentration of 12-OH- 
20: 3(5,8,10) formed under thrombin stimulation 
would be lower than 0.5 x 10e6 M at the early 
stage of aggregation where the monohydroxy 
derivative would act. The physiological activity of 
12-OH-20: 3(5,8,10) would then be a potentiating 
effect on platelet aggregation. 
In conclusion, it seems that the marked increase 
in platelet aggregation associated with saturated 
fat feeding and elevation of 20: 3n-9 in platelet 
phospholipids, might be due to the formation of a 
12-lipoxygenase derivative produced during plate- 
let activation. Moreover, these results confirm that 
the lipoxygenase product metabolites might also 
regulate platelet functions in addition to prostag- 
landins. 
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